Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
- Conditions
- Peripheral Vascular DiseasesAtherosclerosisHyperlipidemiasDiabetes MellitusCoronary Heart DiseaseCarotid Stenosis
- Registration Number
- NCT00536796
- Lead Sponsor
- AstraZeneca
- Brief Summary
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is \<100mg/dl for patients with high risk and \<70mg/dl for patients at very high risk) are screened (hospital-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1096
- Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy
- Patients who do not receive cholesterol-lowering therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cholesterol levels After 4 weeks Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇦🇹Rohrbach, Upper Austria, Austria